COSTS ASSOCIATED WITH INITIATING EMPAGLIFLOZIN VERSUS OTHER ANTIHYPERGLYCEMIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE: A RETROSPECTIVE COHORT STUDY

被引：0
|
作者：
Pimple, P. [1 ]
Raju, A. [2 ]
Stafkey-Mailey, D. [2 ]
Shetty, S. [1 ]
机构：
[1] Boehringer Ingelheim GmbH & Co KG, Ridgefield, CT USA
[2] Xcenda LLC, Palm Harbor, FL USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.605
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB56
引用
收藏
页码：S149 / S149
页数：1
相关论文
共 50 条
  • [11] Trigger finger is associated with risk of incident cardiovascular disease in individuals with type 2 diabetes: a retrospective cohort study
    Mineoka, Yusuke
    Ishii, Michiyo
    Hashimoto, Yoshitaka
    Yuge, Hiroki
    Toyoda, Machiko
    Nakamura, Naoto
    Katsumi, Yasukazu
    Fukui, Michiaki
    [J]. BMJ OPEN DIABETES RESEARCH & CARE, 2021, 9 (01)
  • [12] Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: a nationwide population-based cohort study
    Lim, Jaehyun
    Choi, You-Jung
    Kim, Bong Sung
    Rhee, Tae-Min
    Lee, Hyun-Jung
    Han, Kyung-Do
    Park, Jun-Bean
    Na, Jin Oh
    Kim, Yong-Jin
    Lee, Heesun
    Kim, Hyung-Kwan
    [J]. CARDIOVASCULAR DIABETOLOGY, 2023, 22 (01)
  • [13] Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: a nationwide population-based cohort study
    Jaehyun Lim
    You-Jung Choi
    Bong Sung Kim
    Tae-Min Rhee
    Hyun-Jung Lee
    Kyung-Do Han
    Jun-Bean Park
    Jin Oh Na
    Yong-Jin Kim
    Heesun Lee
    Hyung-Kwan Kim
    [J]. Cardiovascular Diabetology, 22
  • [14] Perinatal outcomes in patients with type 1 versus type 2 diabetes: a retrospective cohort study
    Mission, John
    Cheng, Yvonne
    Yanit, Keenan
    Caughey, Aaron
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2013, 208 (01) : S121 - S121
  • [15] REAL-WORLD COMPARISON OF HOSPITALIZATION COSTS FOR HEART FAILURE IN T2DM PATIENTS WITH CARDIOVASCULAR DISEASE TREATED WITH CANAGLIFLOZIN VERSUS OTHER ANTIHYPERGLYCEMIC AGENTS
    Chen, Y. W.
    Voelker, J.
    Tunceli, O.
    Pericone, C.
    Bookhart, B.
    Durkin, M.
    [J]. VALUE IN HEALTH, 2019, 22 : S146 - S146
  • [16] Cardiovascular Disease in Patients with Type 2 Diabetes and in Patients Starting Empagliflozin Treatment: Nationwide Survey
    Eliasson, Bjorn
    Ekelund, Jan
    Amberntsson, Rikard
    Miftaraj, Mervete
    Svensson, Ann-Marie
    [J]. DIABETES THERAPY, 2019, 10 (04) : 1523 - 1530
  • [17] Cardiovascular Disease in Patients with Type 2 Diabetes and in Patients Starting Empagliflozin Treatment: Nationwide Survey
    Björn Eliasson
    Jan Ekelund
    Rikard Amberntsson
    Mervete Miftaraj
    Ann-Marie Svensson
    [J]. Diabetes Therapy, 2019, 10 : 1523 - 1530
  • [18] Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease
    Kappel, Ben A.
    Lehrke, Michael
    Schutt, Katharina
    Artati, Anna
    Adamski, Jerzy
    Lebherz, Corinna
    Marx, Nikolaus
    [J]. CIRCULATION, 2017, 136 (10) : 969 - 972
  • [19] Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study
    Sheriza Baksh
    Jiajun Wen
    Omar Mansour
    Hsien-Yen Chang
    Mara McAdams-DeMarco
    Jodi B. Segal
    Stephan Ehrhardt
    G. Caleb Alexander
    [J]. Scientific Reports, 11
  • [20] Cost of cardiovascular disease events in patients with and without type 2 diabetes and factors influencing cost: a retrospective cohort study
    Puteh, Sharifa Ezat Wan
    Kamarudin, Noor 'Adilah
    Hussein, Zanariah
    Adam, Noorlita
    Shahari, Mohd Ridzwan
    [J]. BMC PUBLIC HEALTH, 2024, 24 (01)
12345